Chevy Chase, MD, 17 December 2024 – Uncommon Cures, an organization focused on accelerating the development of orphan drugs, has announced a strategic collaboration with Carexso, a leading Site Management organization in the UAE, and PDC FZ LLC, a prominent Contract Research Organization also based in the UAE. This partnership aims to streamline the advancement of clinical trials for orphan drugs across the Middle East, offering new hope to patients with rare diseases who have limited treatment options.
The collaboration will utilize Uncommon Cures' expertise in orphan drug development alongside PDC's and Carexso's regional clinical infrastructure and regulatory knowledge to support a patient-centered clinical trial process. The partnership is driven by the shared goal of expediting access to innovative therapies, aiming to accelerate regulatory pathways and deliver advanced treatment solutions to underserved populations in the Middle East.
Rob Freishtat, President at Uncommon Cures, expressed enthusiasm about the partnership, highlighting Carexso's established presence in the UAE and the Middle East as a critical platform for accelerating clinical trials and creating pathways for faster approvals. Rita Ojeil, COO at Carexso, emphasized the alignment of this partnership with their mission to deliver innovative healthcare solutions to the Middle East, particularly in the field of rare diseases.
In addition to enhancing clinical trial operations, Uncommon Cures, PDC, and Carexso plan to work closely with local stakeholders, including healthcare providers, regulators, and patient advocacy groups, to increase awareness and support for clinical trials in the region. They aim to advocate for streamlined regulatory approval processes to reduce the time needed to bring orphan drugs to patients in urgent need.
Uncommon Cures is dedicated to making vital treatments more accessible to patients with rare diseases through innovative partnerships and regulatory engagement. Carexso specializes in facilitating clinical studies for cutting-edge therapies, particularly in rare diseases and underserved medical areas, while PDC-CRO offers a broad range of drug development services, from early to late phase, tailored to clients' needs.
